Effects of CD40 Stimulation in the Prevention of Human EBV-Lymphomagenesis

References

• Henle W. V., Diehe G., Kohn H., Zur Hausen H., Hughs‐Jones H. Herpes‐type virus and chromosome marker in normal leukocyte after growth with irradiated Burkitt's cells. Science 1967; 157: 1064
   PubMed Web of Science ®Google Scholar
• Straw S. E., Cohen J. I., Tosato G., Meier J. Epstein‐Ban virus infections: biology, pathogenesis, and management. Ann. intern. Med. 1993; 118: 45
   PubMed Web of Science ®Google Scholar
• Mosier D. E., Gulizia R. J., Baird S. M., Wilson D. B. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 1988; 335: 256
   PubMed Web of Science ®Google Scholar
• Murphy W. J., Funakoshi S., Beckwith M., Rushing S. E., Conley D. K., Armitage R. J., Fanslow W. C., Rager H. C., Taub D. D., Ruscetti F. W., Longo D. L. Antibodies to CD40 prevent Epstein‐Barr virus‐mediated human B‐cell lymphomagenesis in severe combined immune deficient mice given human peripheral blood lymphocytes. Blood 1995; 86: 1946
   PubMed Web of Science ®Google Scholar
• Armitage R. J., Maliszewski C. R., Alserson M. R., Grabstein K. H., Spriggs M. K., Fanslow W. C. CD40L: A multi‐functional ligand. Semin. Immunol. 1993; 5: 401
   PubMedGoogle Scholar
• Ledbetter J. A., Shu G., Gallagher M., Clark E. A. Augmentation of normal and malignant B cell proliferation by monoclonal antibody to the B cell‐specific antigen BP50 (CDW40). J. Immunol. 1987; 138: 788
   PubMed Web of Science ®Google Scholar
• Nonoyama S., Hollenbaugh D., Aruffo A., Ledbetter J. A., Ochs H. D. B cell activation via CD40 is required for specific antibody production by antigen‐stimulated human B cells. J. Exp. Med. 1993; 178: 1097
   PubMed Web of Science ®Google Scholar
• Splawski J. B., Fu S. M., Lipsky P. E. Immunoregulatory role of CD40 in human B cell differentiation. J. Immunol. 1993; 150: 1276
   PubMed Web of Science ®Google Scholar
• Aruffo A., Farrington M., Hollenbaugh D., Li X., Milatovich A., Nonoyama S., Bajorath J., Grosmaire L. S., Stenkamp R., Neubauer M., Roberts R. L., Nicolle R. I., Ledbetter J. A., Francke U., Ochs H. D. The CD40 ligand. gp39, is defective in activated T cells from patients with X‐linked hyper‐IgM syndrome. Cell 1993; 72: 291
   PubMed Web of Science ®Google Scholar
• Cutler R. C., Armitage R. J., Conley M. E., Rosenblatt H., Jenkins N. A., Copeland N. G., Bedell M. A., Edelhoff S., Disteche C. M., Simoneaux D. K., Fanslow W. C., Belmont J., Spriggs M. K. CD40 ligand gene defects responsible for X‐linked hyper IgM syndrome. Science 1993; 259: 990
   PubMed Web of Science ®Google Scholar
• Foy T. M., Shephard D. M., Durie F. H., Aruffo A., Ledbetter J. A., Noelle R. J. In vivo CD40‐gp39 interactions are essential for thymus‐dependent humoral immunity. II. Prolonged supression of the humoral immune response by an antibody to the ligand for CD40, gp39. J. Exp. Med. 1993; 178: 1567
   PubMed Web of Science ®Google Scholar
• Ashwell J. D., Longo D. L., Bridges S. H. T‐cell tumor elimination as a result of T‐cell receptor‐mediated activation. Science 1987; 237: 61
   PubMed Web of Science ®Google Scholar
• Beckwith M., Longo D. L., O'Connell C. D., Moratz C. M., Urba W. J. Phorbol ester‐induced, cell‐cycle‐specific, growth inhibition of human B‐lymphoma cell lines. J. Natl. Cancer Inst. 1990; 82: 501
   PubMed Web of Science ®Google Scholar
• Beckwith M., Urba W. J., Ferris D. K., Freter C. E., Kuhns D. B., Moratz C. M., Longo D. L. Anti‐IgM‐mediated growth inhibition of a human B lymphoma cell line is independent of phosphatidylinositol turnover and protein kinase C activation and involves tyrosine phosphorylation. J. Immunol. 1991; 147: 2411
   PubMed Web of Science ®Google Scholar
• Bridges S. H., Kruisheek A. M., Longo D. L. Selective in vivo antitumor effects of monoclonal anti‐I‐A antibody on B cell lymphoma. J. Immunol. 1987; 139: 4242
   PubMed Web of Science ®Google Scholar
• Page D. M., Defranco A. Role of phosphoinositide‐derived second messengers in mediated anti‐IgM‐induced growth arrest of WEHI‐231 B lymphoma cells. J. Immunol. 1988; 140: 3717
   PubMed Web of Science ®Google Scholar
• Ghetie M. A., Picker L. J., Richardson J. A., Tucker K., Uhr J. W., Vitetta E. S. Anti‐CD 19 inhibits the growth of human B‐cell tumor lines in vim and of Daudi cells in SCID mice by inducing cell cycle arrest. Blood 1994; 83: 1329
   PubMed Web of Science ®Google Scholar
• Gruss H. J., Boiani N., Williams D. E., Armitage R. J., Smith C. A., Goodwin R. G. Pleiotropic effects of the CD30 ligand on CD30‐expressing cells and lymphoma cell line. Blood 1994; 83: 2045
   PubMed Web of Science ®Google Scholar
• Funakoshi F., Longo D. L., Beckwith M., Conley D. K., Tsarfaty G., Tsarfaty I., Armitage R. J., Fanslow W. C., Spriggs M. K., Murphy W. J. Inhibition of human B‐cell lymphoma growth by CD40 stimulation. Blood 1994; 83: 2787
   PubMed Web of Science ®Google Scholar
• Holder M. J., Wang H., Milner A. E., Casamayor M., Armitage R., Spriggs M. K., Fanslow W. C., MacLennan I. C. M., Gregory C. D., Gordon J. Suppression of apoptosis in normal and neoplastic human B lymphocytes by CD40 ligand is independent of BcI‐2 induction. Eur. J. Immunol 1993; 22: 2368
   Web of Science ®Google Scholar
• Johnson P. W., Watt S. M., Betts D. R., Daviea D., Jordan S., Norton A. J., Lister T. A. Isolated follicular lymphoma cells are resistant to apoptosis and can he grown in vitro in the CD40/stromal cell system. Blood 1993; 82: 1848
   PubMed Web of Science ®Google Scholar
• Kawata A., Yoshida M., Okazaki M., Yokota S., Barcos M., Seon B. K. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude models in the antitumor efficacy of monoclonal antibody. Cancer Res. 1994; 54: 2688
   PubMed Web of Science ®Google Scholar
• Funakoshi S., Longo D. L., Murphy W. J. Differential in vitro and in vivo antitumor effects mediated by anti‐CD40 and anti‐CD20 monoclonal antibodies against human B‐cell lymphomas. J. Immunotherapy 1996; 19: 93
   PubMed Web of Science ®Google Scholar
• Nakamine H., Masih A. S., Okano M., Taguchi Y., Pirruccello S. J., Davis J. R., Mahlock M. L., Beisel K. W., Kleveland K., Sanger W. G., Purtilo D. T. Characterization of clonality of Epstein‐Barr virus‐induced human B lymphoproliferative disease in mice with severe combined immunodeficiency. Am. J. Pathol. 1993; 142: 139
   PubMed Web of Science ®Google Scholar
• Rowe M., Young L. S., Crocker J., Stokes H., Henderson S., Rickinson A. B. Epstein‐Barr virus EBV)‐associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV‐positive lymphomas in man. J. Exp. Med. 1991; 173: 147
   PubMed Web of Science ®Google Scholar
• Murphy W. J., Bennett M., Anver M. R., Baseler M., Longo D. L. Human‐mouse lymphoid chimeras: host‐vs.‐graft and graft‐vs.‐host reactions. Eur. J. Immunol. 1992; 22: 1421
   PubMed Web of Science ®Google Scholar
• Murphy W. J., Durum S. K., Anver M., Frazier M., Longo D. L. Recombinant human growth hormone promotes human lymphocyte engraftment in immunodeficient mice and results in an increased incidence of human Epstein‐Barr virus‐induced B‐cell lymphoma, Brain. Behav. Immun. 1992; 6: 355
   PubMed Web of Science ®Google Scholar
• Funakoahi S., Beckwith M., Fanslow W. C., Longo D. L., Murphy W. J. Epstein Barr‐virus induced human B‐cell lymphomas arising in huPBL‐SCID chimeric mice: characterization and the role of CD40 stimulation in their treatr and prevention. Pathobiology 1995; 63: 133
   PubMed Web of Science ®Google Scholar
• Nigro J. M., Baker S. J., Prisinger A. C., Jessup J. M., Hostetter R., Cleary K., Binger S. H., Davidson N., Baylin S., Devilee P. Mutatons in the p53 gene occur in diverse human tumor types. Nature 1989; 342: 5
   Web of Science ®Google Scholar
• Bartek J., Bartkova J., Vojtesek B., Staskova Z., Lukas J., Rejthar A., Kovarik J., Midgley C. A., Cannon J. V., Lane D. P. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene. 1991; 6: 1699
   PubMed Web of Science ®Google Scholar
• Mosialos G., Birkenbach M., Yalamanchili R. The EBV transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 1995; 80: 389
   PubMed Web of Science ®Google Scholar
• Ruby J., Bluethmann H., Aguet M., Ramshaw I. A. CD40 ligand has potent antiviral activity. Nature Medicine 1995; 1: 437
   PubMed Web of Science ®Google Scholar